AFYA reports Q1 results on June 22 with analysts having spent the past six months steadily marking down their views on the Brazilian medical education operator — a setup that now sits in tension with cheap-looking valuation multiples and an unusually strong earnings-surprise track record.
The analyst backdrop is the most consequential element here. Since the start of 2026, JP Morgan, BofA Securities, Morgan Stanley, and UBS have each cut their targets, with three of the four also downgrading the rating. Morgan Stanley moved to Underweight in February, the most bearish stance on the stock. JP Morgan, the most recent mover, trimmed its target to $21.50 in late April while maintaining Neutral. The current mean target of roughly $21 implies significant upside from the $14.07 close — but the direction of Street revisions has been uniformly negative, suggesting analysts are still catching down to where the stock already trades rather than making a bullish call.
The valuation case is genuinely interesting, and it cuts against the analyst caution. AFYA trades at just 7.5x trailing earnings and 4.8x EV/EBITDA — compressed multiples for a company that ranks in the 96th percentile universe-wide on EPS surprise. That track record of beating estimates means the bar for a positive reaction tomorrow is lower than the headline sentiment implies. Options traders are not particularly defensive: the put/call ratio is running at 0.48, below its 20-day average of 0.67, suggesting call activity is actually outpacing puts ahead of the print. The contrast with the analyst tone is striking.
Lending conditions tell a calm story. Short interest is minimal at 0.82% of the free float — too low to matter as a directional signal. Borrow availability is normal at roughly 132%, meaning shares are readily available to short if sentiment sours, but there is no evidence of a building short campaign. Cost to borrow has fallen sharply, down 57% over the past month to just 0.60% — consistent with declining demand from borrowers. None of the lending data points to a crowded short position.
The ownership structure is worth noting as context for the print. Headline, Afya's controlling entity, holds nearly 69% of shares, and Bertelsmann holds a further 38% — a tightly held float that amplifies price moves on smaller volume. Insider activity from May 7 was clustered on the sell side across several executives including the CEO and CFO, though at low absolute values and coinciding with share award grants. The net 90-day insider position is actually positive at roughly 167,000 shares, skewed by the awards rather than open-market buying.
On the peer front, the picture is broadly soft. EDU fell 0.4% on the week and YDUQ3 on Bovespa dropped nearly 10%, suggesting the Brazilian and Chinese education space is under pressure broadly. STRA fell 5.7% on the week. The weakness across the peer group adds context to AFYA's own 3.4% decline over the past five days — this looks more like a sector move than a company-specific selloff.
Whether tomorrow's print can reset the narrative around a stock that has now shed more than 20% from where analysts initiated coverage hinges on the strength of enrollment data and any update to margin guidance in the Brazilian medical curriculum business.
See the live data behind this article on ORTEX.
Open AFYA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
